RBC Capital Mkts resumed coverage on Amneal Pharmaceuticals with a new price target
$AMRX
Biotechnology: Pharmaceutical Preparations
Health Care
RBC Capital Mkts resumed coverage of Amneal Pharmaceuticals with a rating of Sector Perform and set a new price target of $5.00